Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), an increase in the notional allocation of Ordinary share ADRs occurred on January 6, 2012. The transaction price was $46.18 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It strictly details the notification of share allocations in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Date: January 6, 2012 (Notification date: January 9, 2012).
- Transaction Price: $46.18 per ADR.
- Participants and Allocations:
- Dr M M Slaoui (Director): 17 ADRs
- Dr K Slaoui (Connected Person): 3 ADRs
- Mr W C Louv (Director): 7 ADRs
- Dr D Pulman (Director): 10 ADRs
- Context: These allocations resulted from a re-valuation of the cash element within the US Retirement Savings Plan.